Oramed Pharmaceuticals (ORMP) Current Leases (2019 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Current Leases came in at $268000.0 in Q1 2026, up 48.07% YoY from $181000.0 in Q1 2025, and down 5.96% on a QoQ basis from $285000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Current Leases (2019 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 8 years of Current Leases data on file, last reported at $268000.0 in Q1 2026.
- Quarterly Current Leases rose 48.07% year-over-year to $268000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268000.0 (up 48.07% YoY) and the FY2025 annual result came in at $285000.0, up 31.94% from the prior year.
- Current Leases retreated to $268000.0 in Q1 2026, from $285000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $285000.0 in Q4 2025 to a low of $181000.0 in Q1 2025.
- A 5-year average of $245470.6 and a median of $247000.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2025 — Current Leases slipped 28.74% — and 2026, when it surged 48.07%.
- Tracing ORMP's Current Leases over 5 years: stood at $247000.0 in 2022, then grew by 8.1% to $267000.0 in 2023, then slipped by 19.1% to $216000.0 in 2024, then surged by 31.94% to $285000.0 in 2025, then fell by 5.96% to $268000.0 in 2026.
- The last three Current Leases figures came in at $268000.0 (Q1 2026), $285000.0 (Q4 2025), and $271000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 249,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249,000.00 |
| Mar 31, 2026 | 268,000.00 |
| Dec 31, 2025 | 285,000.00 |
| Sep 30, 2025 | 271,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Mar 31, 2025 | 181,000.00 |
| Dec 31, 2024 | 216,000.00 |
| Sep 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 267,000.00 |
| Sep 30, 2023 | 251,000.00 |
| Jun 30, 2023 | 236,000.00 |
| Mar 31, 2023 | 242,000.00 |
| Dec 31, 2022 | 247,000.00 |
| Sep 30, 2022 | 228,000.00 |
| Jun 30, 2022 | 233,000.00 |
| Mar 31, 2022 | 237,000.00 |
| Nov 30, 2021 | 130,000.00 |
| Aug 31, 2021 | 130,000.00 |